AvantGuard, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

AvantGuard, Inc. - overview

Established

2018

Location

Ithaca, NY, US

Primary Industry

Chemicals

About

AvantGuard, Inc. , based in New York, US, develops pioneering antimicrobial technologies. Their key product, Avantamine™, effectively combats pathogens while minimizing resistance, serving critical sectors like healthcare and food safety. AvantGuard, Inc.


is dedicated to creating advanced antimicrobial solutions, with its headquarters located in Ithaca, US. Founded in 2018 by Greg Bertsch, the company has executed a total of 6 deals, the most recent being a Seed round on May 11, 2023, raising USD 1. 23 mn from investors including Blue Ledge Capital, Launch NY, Red Bear Angels Management, and SOSV. The cumulative funding raised by AvantGuard amounts to USD 1.


23 mn, with a current company valuation of USD 44. 96 mn. AvantGuard specializes in developing innovative antimicrobial technologies, with Avantamine™ as its flagship product. This molecule uniquely mimics the body's immune response to target bacteria, viruses, and fungi, and can be used as an antiseptic, disinfectant, or surface coating.


Avantamine™ finds significant applications in healthcare settings, aiming to reduce life-threatening infections in vulnerable populations, and is marketed primarily in North America to healthcare facilities, medical device manufacturers, and the food and beverage industry. AvantGuard operates on a revenue model that focuses on B2B transactions, providing antimicrobial solutions through direct sales to hospitals and medical facilities in critical need of infection control. Their offerings, including Avantamine™, are sold via bulk orders and supply agreements, with pricing reflecting the advanced technology's value in improving health outcomes and minimizing costs linked to hospital-acquired infections. Following the Seed funding raised on May 11, 2023, AvantGuard plans to utilize the USD 1.


23 mn to enhance the development of its antimicrobial technologies, expand its team by hiring more scientists, and broaden its global market presence. Specific target regions and new product launches will be further defined as the company progresses with its growth initiatives.


Current Investors

Launch NY, SOSV, National Science Foundation

Primary Industry

Chemicals

Sub Industries

Commodity Chemicals

Website

www.avantguardinc.com

Verticals

Manufacturing

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.